New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Stock Information for Inovio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inovio Pharmaceuticals Inc.

INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
INOVIO Announces Pricing of $30 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.